Updated and revised Russian consensus on the use of multilevel injections of abobotulinumtoxin A in children

One of the modern components of complex rehabilitation of patients with spasticity is the use of botulinum toxin type A (BTA) preparations. International experience with the use of botulinum therapy in children spans more than 30 years. Abobotulinum toxin A has been used to treat spasticity since 1994. Clinical studies have shown the high efficacy of abobotulinumtoxin A in relieving spasticity of the lower and upper extremities in cerebral palsy (CP) and other disorders, which is associated with a significant increase in muscle tone, thereby increasing motor skills and achieving individual patient goals. The article presents a consensus of Russian experts on the approach to selecting target muscles and calculating the dose of abobotulinumtoxin A in multilevel injections, and discusses the planning of repeat injections, ethical and legal aspects of botulinum therapy in children, the combination of botulinum therapy with other methods of correcting spasticity in CP, the use of BTA in dystonia and sialorrhea, and factors potentially influencing the effectiveness of botulinum therapy. This consensus summarizes the views of Russian experts on creating an injection protocol depending on individual clinical data and treatment goals, which can be used as a guide for practical work.

1. Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3. doi: 10.1007/s11910-020-1022-z

2. Gusev EI, Kostenko EV, Boiko AN. Spasticity. Clinic, diagnosis and comprehensive rehabilitation with the use of botulinum therapy. 3rd ed., revised and expanded. Moscow: GEOTARMedia; 2023. 312 p. (In Russ.).

3. Klochkova OA, Kurenkov AL. Botulinum therapy for cerebral palsy: practical tips and ultrasound control. 2nd ed., revised and expanded. Moscow: MEDpress-inform; 2023 (In Russ.).

4. Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010 Jan;14(1):45-66. doi: 10.1016/j.ejpn.2009.09.005. Epub 2009 Nov 14.

5. Love SC, Novak I, Kentish M, et al; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010 Aug;17 Suppl 2:9-37. doi: 10.1111/j.1468-1331.2010.03126.x

6. Fehlings D, Novak I, Berweck S, et al; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol. 2010 Aug;17 Suppl 2:38-56. doi: 10.1111/j.1468-1331.2010.03127.x

7. Vova JA, Green MM, Brandenburg JE, et al. A consensus statement on the use of botulinum toxin in pediatric patients. PM R. 2022 Sep;14(9):1116-42. doi: 10.1002/pmrj.12713. Epub 2021 Nov 26.

8. Kurenkov AL, Klochkova OA, Zmanovskaya VA, et al. The First Russian Consensus on the Multilevel Abobotulinumtoxin A Injections in Spastic Forms of Cerebral Palsy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11):121- 30. doi: 10.17116/jnevro2016116111121-130 (In Russ.).

9. Kurenkov AL, Kuzenkova LM, Bursagova BI, et al. Russian Consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):117-25. doi: 10.14412/2074-2711-2022-2-117-125 (In Russ.).

10. Klochkova OA, Kurenkov AL. Priorities and goals of botulinum toxin A treatment in cerebral palsy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2):102-8. doi: 10.17116/jnevro2019119021118 (In Russ.).

11. Mathevon L, Bonan I, Barnais JL, et al. Adjunct therapies to improve outcomes after botulinum toxin injection in children: A systematic review. Ann Phys Rehabil Med. 2019 Jul;62(4):283- 90. doi: 10.1016/j.rehab.2018.06.010. Epub 2018 Jul 29.

12. World Health Organization. International Classification of Functioning, Disability and Health (ICF). Geneva: World Health Organization; 2001. 13. World Health Organization. Towards A Common Language For Functioning, Disability And Health. Geneva: World Health Organization; 2002.

13. Mayston M. Intervention planning, implementation, and evaluation. In: Cerebral palsy: science and clinical practice. Eds Dan B, Mayston M, Paneth N, Rosenbloom L. London: Mac Keith Press; 2014. P. 287-311.

14. Tilton A, Russman B, Aydin R, et al. AbobotulinumtoxinA (Dysport®) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy. J Child Neurol. 2017 Apr;32(5):482-7. doi: 10.1177/0883073816686910. Epub 2017 Jan 9.

15. Delgado MR, Tilton A, Carranza-Del Rio J, et al; Dysport in PUL study group. Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study. Dev Med Child Neurol. 2021 May;63(5):592-600. doi: 10.1111/dmcn.14733. Epub 2020 Nov

16.

17. Bohn E, Goren K, Switzer L, et al. Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis. Dev Med Child Neurol. 2021 Sep;63(9):1038-50. doi: 10.1111/dmcn.14874. Epub 2021 Mar 27. 18. Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial. Pediatrics. 2016 Feb;137(2):e20152830. doi: 10.1542/peds.2015-2830. Epub 2016 Jan 26.

18. Delgado MR, Bonikowski M, Carranza J, et al. Safety and Efficacy of Repeat Open-Label AbobotulinumtoxinA Treatment in Pediatric Cerebral Palsy. J Child Neurol. 2017 Nov;32(13):1058-64. doi: 10.1177/0883073817729918. Epub 2017 Sep 15.

19. Paget SP, Swinney CM, Burton KLO, et al. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy. Dev Med Child Neurol. 2018 Nov;60(11):1172-7. doi: 10.1111/dmcn.13995. Epub 2018 Aug 26.

20. Kurenkov AL, Kuzenkova LM, Fisenko DA, et al. Changes of the spasticity patterns in children with cerebral palsy GMFCS III at the age of 2 to 12 years. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6):36-44. doi: 10.17116/jneuro202012006136 (In Russ.).

21. Kurenkov AL, Klochkova OA, Kuzenkova LM, et al. Multilevel botulinum toxin treatment in severe spastic forms of cerebral palsy (GMFCS IV–V). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12):57-66. doi: 10.17116/jnevro202012012157 (In Russ.).

22. Thomason P, Graham KH. Rehabilitation of children with cerebral palsy after single-event multilevel surgery (Chapter 18). In: Rehabilitation in Movement Disorders. Cambridge University Press; 2013. P. 203-16. doi: 10.1017/CBO9781139012942.019 24. Multani I, Manji J, Hastings-Ison T, et al. Botulinum Toxin in the Management of Children with Cerebral Palsy. Paediatr Drugs. 2019 Aug;21(4):261-81. doi: 10.1007/s40272-019-00344-8

23. Klochkova OA, Kurenkov AL, Karimova KhM, et al. Multilevel botulinum toxin A (abobotulinumtoxin A) injections in spastic forms of cerebral palsy: retrospective analysis of 8 russian centers experience Pediatricheskaja farmakologija. 2016;13(3):259-69. doi: 10.15690/pf.v13i3.1576 (In Russ.).

24. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015 Mar;15(1):1- 9. doi: 10.1007/s40268-014-0077-1

25. Orlova OR, Timerbaeva SL, Khat'kova SE, et al. Conversion ratio between different botulinum neuroprotein product in neurological practice. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):132- 41. doi: 10.17116/jnevro201711791132-141 (In Russ.).

26. Dorf SR, Fonseca AR, Sztajnbok FR, et al. The state of the art in therapeutic administration of botulinum toxin in children with cerebral palsy: an integrative review. Rev Paul Pediatr. 2024 Mar 25;42:e2023093. doi: 10.1590/1984-0462/2024/42/2023093

27. Morgan C, Fetters L, Adde L, et al. Early Intervention for Children Aged 0 to 2 Years With or at High Risk of Cerebral Palsy: International Clinical Practice Guideline Based on Systematic Reviews. JAMA Pediatr. 2021 Aug 1;175(8):846- 58. doi: 10.1001/jamapediatrics.2021.0878

28. Yang H, Chen S, Shen J, et al. Safety and Efficacy of Botulinum Toxin Type A in Children With Spastic Cerebral Palsy Aged <2 Years: A Systematic Review. J Child Neurol. 2023 May;38(6-7):454-65. doi: 10.1177/08830738231183484. Epub 2023 Jul 10.

29. Bourseul JS, Molina A, Lintanf M, et al. Early Botulinum Toxin Injections in Infants With Musculoskeletal Disorders: A Systematic Review of Safety and Effectiveness. Arch Phys Med Rehabil. 2018 Jun;99(6):1160-76.e5. doi: 10.1016/j.apmr.2017.11.013. Epub 2017 Dec 27.

30. Klochkova OA, Kurenkov AL, Mamed"yarov AM, et al. Botulinum toxin A injection precision control at spastic forms of cerebral palsy: choosing methodology. Pediatricheskaya farmakologiya. 2013;10(2):80- 6. doi: 10.15690/pf.v10i2.648 (In Russ).

31. Klochkova OA, Kurenkov AL. Botulinum therapy for cerebral palsy: practical tips and ultrasound control. Moscow: MEDpress-inform; 2020. 248 p. (In Russ.).

32. Klochkova OA, Kolesnikova EP, Zinenko DYu, Berdichevskaya EM. Selective dorsal rhizotomy in treatment of spasticity in patients with cerebral palsy. Voprosi sovremennoy pediatrii. 2022;21(1):19-28. doi: 10.15690/vsp.v21i1.2382 (In Russ.).

33. Speyer R, Cordier R, Kim JH, et al. Prevalence of drooling, swallowing, and feeding problems in cerebral palsy across the lifespan: a systematic review and meta-analyses. Dev Med Child Neurol. 2019 Nov;61(11):1249-58. doi: 10.1111/dmcn.14316. Epub 2019 Jul 22.

34. Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clin Neurol Neurosurg. 2009 Jan;111(1):79-82. doi: 10.1016/j.clineuro.2008.09.001. Epub 2008 Nov 1.

35. Klochkova OA, Kurenkov AL, Karimova HM, et al. Sialorrhea in patients with cerebral palsy: the effectiveness of botulinum therapy. Pediatricheskaya farmakologiya. 2015;12(4):398- 406. doi: 10.15690/pf.v12i4.1420 (In Russ.).

36. Picelli A, Santamato A, Chemello E, et al. Adjuvant treatments associated with botulinum toxin injection for managing spasticity: An overview of the literature. Ann Phys Rehabil Med. 2019 Jul;62(4):291-6. doi: 10.1016/j.rehab.2018.08.004. Epub 2018 Sep 13.

37. Novak I, Cusick A, Lannin N. Occupational therapy home programs for cerebral palsy: double-blind, randomized, controlled trial. Pediatrics. 2009 Oct;124(4):e606- 14. doi: 10.1542/peds.2009-0288. Epub 2009 Sep 21.

38. Novak I, Berry J. Home program intervention effectiveness evidence. Phys Occup Ther Pediatr. 2014 Nov;34(4):384-9. doi: 10.3109/01942638.2014.964020. Epub 2014 Oct 15.

39. Artemenko AR, Kurenkov AL. Botulinum toxin: yesterday, today, tomorrow. Nervnomyshechnye bolizni. 2013;2(4):6-18. doi: 10.17650/2222-8721-2013-0-2-6-19 (In Russ.).

40. Mathevon L, Declemy A, Laffont I, Perennou D. Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review. Ann Phys Rehabil Med. 2019 Jul;62(4):241-51. doi: 10.1016/j.rehab.2019.03.004. Epub 2019 Apr 11.

41. Timerbaeva SL, editor. The ABC of botulinum toxin therapy: scientific and practical publication. Moscow: Prakticheskaja medicina; 2018. 416 р. (In Russ.).